Back to top

Abivax price target raised to $180 from $132 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Abivax (ABVX) to $180 from $132 and keeps an Overweight rating on the shares. Since the topline ma...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Abivax SA Sponsored ADR (ABVX)